Context: GH deficiency is common in childhood cancer survivors. In a previous report, although we did not find an increase in the risk of disease recurrence in survivors treated with GH, GH-treated survivors did have an increased risk of developing a second neoplasm (SN) (rate ratio, 3.21).
G
H DEFICIENCY IS one of the most common endocrinopathies that develop in childhood cancer survivors (1, 2) . GH, which has been used for more than 25 yr, appears to improve final height of childhood cancer survivors (3, 4) . However, there have been safety concerns about the use of GH because of the mutagenic and carcinogenic properties of GH and IGF-I (5, 6).
To date, multiple reports, including our previous study, have not shown an increased risk of disease recurrence in childhood cancer survivors treated with GH (7-10), although potential selection bias makes the results of these studies difficult to interpret. However, our previous report indicated that cancer survivors treated with GH had a 3-fold increased risk of developing a second neoplasm (SN) compared with survivors not so treated (9) .
In this study we have reassessed the risk of our initial cohort of GH-treated survivors developing an SN after an additional 32 months of follow-up.
Subjects and Methods

Childhood Cancer Survivor Study (CCSS)
The details of the conduct and characteristics of the CCSS, also known to study participants as the Long-Term Follow-Up Study, have been published previously (11) . In brief, the CCSS is a retrospective cohort of 5-yr survivors of childhood cancer diagnosed before age 21 yr, between the years 1970 and 1986, and treated at one of 26 contributing centers in the United States or Canada. Subjects with benign tumors, including craniopharyngioma, were excluded from the study. The study was approved by the institutional review board at each participating center, and each participant or parent, if participant was less than 18 yr of age, signed informed consent before participation.
Participation in the Long-Term Follow-Up Study consisted of completion of a 24-page questionnaire (complete questionnaire available at http://www.cancer.umn.edu/ccss), consent for release of medical records, and consent to be contacted in the future to update health history and to consider participation in ancillary research projects. The baseline questionnaire contained questions regarding a broad spectrum of topics, including demographics, medical conditions diagnosed by a doctor, prescription medications taken during the past 2 yr, and development of subsequent neoplasms. For individuals who indicated that they had been diagnosed with a subsequent neoplasm, verification of the diagnosis was made by requesting copies of the pathology report from the treating institution. All submitted material was reviewed by a single
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pathologist (Sue Hammond, M.D., Children's Hospital, Columbus, OH). In the current analysis, subjects with SN do not include the occurrence of nonmelanoma skin cancers.
Detailed medical information was abstracted from the medical record of each participant (copy of abstraction forms available at http://www. cancer.umn.edu/ccss). Data collected included all treatments for the primary diagnosis, including the initial treatment, treatment for any relapse, and preparatory regimens for bone marrow transplant. Information about cancer treatment included qualitative information on 42 chemotherapeutic agents, quantitative information on 22 selected chemotherapeutic agents, surgeries performed from the time of diagnosis, and quantitative radiation data on field size, site, and dose.
The CCSS cohort consists of 14,352 survivors. Two hundred forty-four survivors were excluded from this analysis: 204 because of missing data regarding their exposure to GH treatment; 38 for diagnosis of a second tumor 5 yr or less from their primary cancer diagnosis; and two because of missing data on time of diagnosis of a second tumor. Thus, 14,108 survivors were eligible for this analysis, including 361 individuals previously documented to have been treated with GH (9) . Details of their exposure to GH including start and stop date of GH, dose of GH, and height data were obtained from their physicians. All but two of the 361 survivors who were treated with GH began treatment before age 18 yr. A total of 3946 survivors (28%) were either lost to follow-up or refused participation in the current extended follow-up; this included 76 survivors treated with GH (21%) and 3870 survivors not treated with GH (28%; P Ͻ 0.003). An additional 60 survivors reported that they had started GH therapy during this 32-month extended follow-up. The data from these individuals were omitted from this analysis because of lack of detailed information on their GH exposure.
Statistical analysis
The relationship between GH therapy and the time to development of an SN, and death, were examined using a time-dependent Cox model (12) . An adjustment for potential confounding factors such as age, sex, chemotherapy, alkylating agent score, and radiation were incorporated into the model. A test of association between the GH administration and SN is based on the score test derived from the partial likelihood of the model. The test examines whether ␤ ϭ 0, a result that implies that GH use does not alter the risk of SN. SN experienced within 5 yr of diagnosis were excluded from the analysis because of the CCSS eligibility criterion of survival of at least 5 yr after the original cancer diagnosis.
Results
The clinical characteristics of survivors, those both treated and not treated with GH, are summarized in Table 1 . During this 32-month extended follow-up, five additional solid SN were reported for a total of 20 SN (Table 2) . Among the survivors of central nervous system (CNS) tumors, there were three additional cases of meningioma and one new case of thyroid carcinoma. One of the neuroblastoma survivors developed an astroglial CNS tumor. There were no secondary leukemias found in this updated analysis, as was the case in our previous report (9) . No new SN were reported among survivors of acute leukemia. A total of 555 SN were reported in the survivors not treated with GH, including 211 that occurred during this 32-month extended follow-up.
The risk factors associated with the development of an SN, in both the univariate and multivariate models, are shown in Table 3 . The time-dependent Cox model revealed that after adjusting for potential cofounders such as age at diagnosis, sex, radiation, and alkylating agent effects, the rate ratio (RR) of GH-treated survivors developing an SN was 2.15 [95% confidence interval (CI), 1.33-3.47; P ϭ 0.002] compared with survivors not treated with GH. The number of SN in GHtreated survivors compared with the number of SN in survivors who were not treated with GH is illustrated in Fig. 1 . When the survivors were stratified by original cancer diagnosis, the differences between survivors who did and did not receive GH did not reach statistical significance for any of the diagnostic groups; the RR of developing an SN for survivors of leukemia was 2.3 (95% CI, 0.9 -5.8; P ϭ 0.07) and for CNS tumor survivors was 1.42 (95% CI, 0.67-3.02; P ϭ 0.35). There was no association between dose and duration of GH therapy and the risk of developing an SN (P ϭ 0.1 and P ϭ 0.8, respectively).
In the GH-treated survivors, meningiomas were the most common SN (nine of 20). In the survivors who were not treated with GH, there were a total of 62 cases that developed a meningioma. All GH-treated survivors who developed a meningioma had received radiation to the brain/head. The latency period for developing a meningioma in the GHtreated group was 12.2 yr, compared with 19 yr in the survivors not treated with GH (P Ͻ 0.01). In the GH-treated group, six survivors were diagnosed with a meningioma after completing their GH treatment, and three survivors developed a meningioma while they were still receiving GH treatment. A total of 1570 survivors have died, including 33 of the 361 GH-treated survivors and 1537 survivors not treated with GH. The percentage of deaths due to an SN was similar for survivors treated with GH compared with survivors not so treated (25 vs. 13%; P ϭ 0.16). After adjusting for the covariate effects of age at diagnosis, sex, radiation, and chemotherapy AA, Alkylating agent; ALL, acute lymphoblastic leukemia; B, brain; Chemo, chemotherapy; F, face; LE, lower extremity; NHL, non-Hodgkin's lymphoma; nspx, nasopharynx; PNET, primitive neuroectodermal tumor; RT, radiation therapy; S, spine; M, male; F, female; N, neck; TBI, total body irradiation.
a New cases. in the multivariate model, the RR of death for GH-treated patients compared with those not treated with GH was 1.20 (95% CI, 0.81-1.79; P ϭ 0.36).
Discussion
In this updated analysis that includes an additional 32 months of follow-up of our initial cohort, we have shown that the risk of developing an SN in childhood cancer survivors treated with GH remains elevated compared with the risk seen in survivors not treated with GH. Although this finding is in agreement with our previous report (9), our current findings suggest that the risk appears to diminish with increasing length of follow-up (i.e. RR 2.15 vs. RR 3.21).
Of the SN noted among our survivors treated with GH, we found that meningiomas were the most common. In the current study, all GH-treated survivors who developed a meningioma had received some radiation to the brain as part of the treatment for their primary cancer. Meningiomas are known to develop after radiation to the head for benign and malignant conditions (13) (14) (15) . For survivors of CNS tumors, meningiomas are among the most common SN observed after therapeutic radiation to the brain (16 -18) .
Because meningiomas may remain asymptomatic for prolonged periods of time (19, 20) , the possibility of surveillance/detection bias needs to be considered when interpreting our results. Thus, if survivors treated with GH had been subjected to more consistent and frequent medical surveillance (e.g. magnetic resonance imaging of the head) compared with survivors not treated with GH, our results could have overestimated the risk (21) . We did observe a shorter latency period between radiation and the diagnosis of meningiomas in the GH-treated group compared with the group not so treated. Although this could represent differences in how the two groups were followed and scrutinized, we cannot exclude a true biological effect of GH on the development and progression of the meningiomas (5). In the current study, we did not have sufficient data to determine whether surveillance bias played a role in our findings; this can be determined best through a long-term prospective study.
In our previous study, we noted no cases of secondary leukemia but an excess number of secondary osteogenic sarcomas among leukemia survivors treated with GH. In this extended follow-up study, we also failed to detect any cases of secondary leukemia among the survivors treated with GH. No additional cases of osteogenic sarcoma or any other SN were found in leukemia survivors treated with GH in this extended follow-up, which is reassuring. Although the lostto-follow-up/refusal rates were lower for the GH-treated survivors compared with survivors not so treated, it is unlikely that this difference (21 vs. 28%) has resulted in an appreciable bias in our estimates of RR of SN.
In conclusion, this updated analysis confirms our previous report that childhood cancer survivors treated with GH appear to have an elevated risk of developing a secondary solid tumor compared with survivors not so treated. However, the elevation of risk resulting from GH use appears to decrease with increasing length of follow-up, and the overall risk remains small. This risk should be weighed against the potential benefits of GH therapy in cancer survivors. Our findings indicate a need for continued surveillance of childhood cancer survivors treated with GH.
